文献速递肝病

直接抗病毒药物时代丙型肝炎病毒的再治疗:美国预测

Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.
PubMed 文献 · Aliment Pharmacol Ther · 2018-01-29

BACKGROUND: The introduction of oral direct-acting antivirals (DAAs) has dramatically changed the landscape of HCV treatment. However, a small percentage of patients fail to achieve sustained virologic response (SVR).…

核心结论

  • 即使在高效DAA时代,仍有相当数量患者无法获得SVR并需要再治疗选择。
  • 及时有效的再治疗对预防HCV长期后遗症至关重要。

研究设计与样本

  • 采用数学模型模拟美国HCV临床管理,包括筛查、治疗和疾病进展的实施。
  • 模拟不同波次的DAA治疗,并使用真实世界数据提取SVR率和可用疗法的市场份额。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The introduction of oral direct-acting antivirals (DAAs) has dramatically changed the landscape of HCV treatment. However, a small percentage of patients fail to achieve sustained virologic response (SVR). Understanding the number of people who fail on DAAs and require re-treatment is important for budget impact and disease burden projections. AIM: To quantify the number of HCV patients who fail to achieve SVR on oral DAAs (NS5A vs. non-NS5A) and require re-treatment. METHODS: We used a mathematical model to simulate clinical management of HCV in the USA, which included the implementation of HCV screening, treatment, and disease progression. We simulated different waves of DAA treatment and used real-world data to extract SVR rates and market shares of available therapies. RESULTS: Our model projected that the number of people living without viraemia (i.e. cured) would increase from 0.70 million in 2014 to 1.78 million by 2020. Between 2014 and 2020, 1.50 million people would receive treatment with DAAs, of whom 124 000 (8.3%) are projected to fail to achieve SVR. Among those treatment failures, 66 600 (53.7%) patients would fail treatment with NS5A inhibitors and 69 600 (56.1%) would have cirrhosis. During the same period, 34 200 people would progress to decompensated cirrhosis and 27 300 would develop hepatocellular carcinoma after failing to achieve SVR. CONCLUSIONS: Even in the era of highly effective DAAs, a significant number of patients will fail to achieve SVR and will require re-treatment options. Timely and effective re-treatment is essential to prevent the long-term sequelae of HCV.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chhatwal J, Chen Q, Ayer T, et al. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther. 2018. PMID: 29377245. doi:10.1111/apt.14527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。